News board

Updated May 30, 2026 200
Endpoints News May 30, 2026
#ASCO26: Grail’s cancer blood test isn’t ready for widespread use, experts say
FierceBiotech May 30, 2026
In next-gen IO race in NSCLC, BioNTech/BMS and Pfizer are divided on overall survival approach
Cell May 30, 2026
Decoding the spatiotemporal development of human meninges
Cell May 30, 2026
Fronto-insular circuit mechanisms of accelerated intermittent theta burst stimulation
Cell May 30, 2026
Physiological brain clearance architecture revealed by neuronal protein tracing
FierceBiotech May 30, 2026
ASCO: Gilead touts ADC ovarian cancer data as proof Tubulis buyout was ‘a good deal’

Life science stocks

0 / 49 Live / tracked Syncing
Loading live quotes Connecting market feeds

Where life science meets commercial signal.

Archive Oldest
Lead
Endpoints News May 30, 2026

#ASCO26: Grail’s cancer blood test isn’t ready for widespread use, experts say

Grail's blood test, which it has pitched as a way to spot a variety of cancers early in their growth, still isn't ready to be used as a regular screening tool, experts not involved with ...

Open
Endpoints News May 30, 2026
Can AI do scientific research?; The 'magic bullet' search has faded in immunotherapy; and more
Endpoints News May 29, 2026
Next FDA user fee deal is under review at the White House
Endpoints News May 29, 2026
Post-Hoc: Lilly gets more secretive and hides Phase 1 pipeline
Latest Archive
FierceBiotech May 30, 2026
In next-gen IO race in NSCLC, BioNTech/BMS and Pfizer are divided on overall survival approach
Cell May 30, 2026
Decoding the spatiotemporal development of human meninges
Cell May 30, 2026
Fronto-insular circuit mechanisms of accelerated intermittent theta burst stimulation
Cell May 30, 2026
Physiological brain clearance architecture revealed by neuronal protein tracing
FierceBiotech May 30, 2026
ASCO: Gilead touts ADC ovarian cancer data as proof Tubulis buyout was ‘a good deal’
Illumina May 30, 2026
Illumina Ducks DNA Sequence Rival's Antitrust Suit, For Now - Law360
BioPharma Dive May 29, 2026
At ASCO, Merck makes case for a ‘cornerstone’ cancer drug
BioPharma Dive May 29, 2026
Bristol Myers unveils data for one of its next-gen blood cancer drugs
Clinical OMICs May 29, 2026
Teclistamab Outperforms Standard Therapy in Relapsed Multiple Myeloma
Clinical OMICs May 29, 2026
AI Chatbots Do Not Consistently Deliver Accurate Health Responses
FierceBiotech May 29, 2026
Legend scientific founder returns to ASCO with new ambition for high-yield, non-gene-editing CAR-T platform
BioWorld May 29, 2026
Money raised by biopharma
BioWorld May 29, 2026
Biopharma money raised: Jan. 1-May 28, 2026
BioPharma Dive May 29, 2026
Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks
BioWorld May 29, 2026
Other news to note for May 29, 2026
BioWorld May 29, 2026
Regulatory actions for May 29, 2026
BioWorld May 29, 2026
China launches long-awaited drug data protection rules
BioWorld May 29, 2026
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal